| The Centers for Disease Control and Prevention has issued a health alert in response to limited supplies of nirsevimab, an antibody drug designed to protect infants from the respiratory disease RSV. The CDC is now advising pediatricians and other health-care providers to prioritize administering certain doses of the monoclonal antibody, sold under the brand name Beyfortus, to infants with the highest risk of developing severe respiratory syncytial virus. The update comes as RSV cases have started to rise in parts of the United States with the onset of cold and flu season, creating a conundrum for many pediatricians. | 
No comments:
Post a Comment